Advanced Ultrasound Contrast Agent Generation and Monitoring System
Legal Citation
Summary of the Inventive Concept
A next-generation system for producing and monitoring ultrasound contrast agents, leveraging advanced nanotechnology, machine learning, and real-time sensing to create more stable and tailored microspheres.
Background and Problem Solved
The original patent disclosed methods for preparing phospholipid-based ultrasound contrast agents, but these methods are limited by the susceptibility of phospholipid formulations to divalent metal cations. The new inventive concept addresses this limitation by introducing novel, calcium-resistant phospholipid variants, advanced nanotechnology-based blending, and real-time monitoring of precipitation.
Detailed Description of the Inventive Concept
The system comprises a microfluidic device for controlled phospholipid blending, a metal-ion-free chamber for minimizing precipitation, and a sensor array for detecting changes in solution conductivity. The system utilizes machine learning algorithms to predict optimal phospholipid blends and concentrations based on desired microsphere properties. The novel phospholipid composition is divalent-metal-cation-free, comprising a blend of synthetic, calcium-resistant phospholipid analogs and a proprietary solvent system for enhanced microsphere stability.
Novelty and Inventive Step
The new claims introduce a paradigm shift in ultrasound contrast agent generation and monitoring by incorporating advanced nanotechnology, machine learning, and real-time sensing. The use of novel, calcium-resistant phospholipid variants and metal-ion-free chambers provides a non-obvious solution to the problem of phospholipid precipitation.
Alternative Embodiments and Variations
Alternative embodiments may include variations in the microfluidic device design, different machine learning algorithms for phospholipid blend prediction, and modifications to the sensor array for detecting changes in solution conductivity. Additional variations may include the use of different solvent systems or phospholipid analogs.
Potential Commercial Applications and Market
The advanced ultrasound contrast agent generation and monitoring system has significant commercial potential in the medical imaging industry, particularly in the development of more effective and targeted ultrasound contrast agents for diagnostic and therapeutic applications.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K49/223 |
| A | A61 | A61B8/481 |
| A | A61 | A61K49/226 |
| A | A61 | A61K49/227 |
| C | C07 | C07F9/09 |
| C | C07 | C07F9/106 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering and pharmaceutical nanotechnology, specifically ultrasound contrast agent formulation and microfluidic systems for medical imaging diagnostics. Requires advanced knowledge of phospholipid chemistry, microfluidic device design, and molecular engineering techniques
Person of Ordinary Skill (PHOSITA) Profile
A PhD-level researcher with expertise in pharmaceutical nanotechnology, possessing advanced skills in lipid chemistry, microfluidic system design, machine learning applications in biomedical engineering, and ultrasound contrast agent development
Obviousness Rationale
A PHOSITA would recognize that the PTD's machine learning-driven microfluidic approach for ultrasound contrast agent generation represents an incremental and predictable technological advancement over the source patent's phospholipid formulation methods. The disclosed variations leverage known techniques in nanotechnology and computational modeling to address inherent challenges in microsphere stability, utilizing standard engineering problem-solving approaches that would be apparent to a skilled practitioner in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,646 |
|---|---|
| Title | Methods for making ultrasound contrast agents |
| Assignee(s) | Lantheus Medical Imaging, Inc. |